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Abstract
Introduction: Despite many efforts to develop new chemotherapies for metastatic upper gastrointestinal (GI) cancer, overall 
prognosis continues to be fatal, particularly in gastric and pancreatic cancer. Many of these patients deserve second-or 
third-line treatment after failure of ﬁ  rst-line chemotherapy. Therefore, we analysed toxicity and response rate of weekly 
docetaxel after failed upfront regimes in these upper GI cancer patients.
Patients and Methods: Between 2001 and 2006, 18 patients received docetaxel based regimes (35 mg/m² weekly) after 
informed consent. Response rates were determined using RECIST criteria or tumor progression if clinically evident. Toxicities 
were graded based on NCI CTC criteria (version 2). Most patients had gastric cancer (13/18). The remaining entities 
comprised of bilio-pancreatic cancer (5/18).
Results: Docetaxel was administered as 2nd line therapy in 28% (5/18), 3rd line therapy in 56% (10/18) and 4th or 5th line 
therapy in 17% (3/18). The average docetaxel dose was 38 mg/m² (Median: 35 mg/m²) once weekly. Over a treatment 
duration of 14.7 weeks, the average dosage was 58 gr per patient and week. Overall, docetaxel was well tolerated with only 
few chemotherapy-associated toxicities (Grade 3/4), including nausea (17%), polyneuropathy (17%), anorexia (11%), 
neutropenia (6%) and leukopenia (17%).
Docetaxel administration did not achieve any complete responses (CR) and one (5.6%) partial response (PR) was seen 
(1/18). In addition 5 patients (27.8%) had stable disease (SD), thus inducing a tumor control rate of 33.3% (6/18). Median 
progression-free survival was 2.4 months for all patients, 2.1 months in the gastric-cancer and 2.4 months in the bilio-
pancreatic cancer subgroups respectively. After ﬁ  rst docetaxel administration median survival for all patients was 4.5 months, 
patients with gastric cancer survived for 4.9 months whereas patients suffering from bilio-pancreatic carcinoma survived 
for 4.2 months. However, taken together 27% (5/18) had a remarkable overall survival of more than 2.5 years.
Discussion: In severely pretreated patients, with documented chemoresistant GI tumors, weekly docetaxel was well tolerated, 
presented good tumor control rate and overall survival. Therefore, this regimen may be used as salvage treatment in individual 
patients with upper GI cancers.
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Introduction
Both, patients with metastatic gastric or pancreatic cancers very often present with very short and fatal 
outcome despite their initial beneﬁ  ts of upfront ﬁ  rst-line palliative chemotherapy. These both cancer 
types contribute to at least ten% of the cancer related mortality in the United States (Jemal et al. 2005; 
Bray et al. 2002).
Despite many efforts to control tumor progression with new chemotherapeutic agents, the overall 
mortality has not signiﬁ  cantly changed over the last years. (Hohenberger, Gretschel, 2003; Pyrhonen et al. 
1995; Murad et al. 1993; Glimelius et al. 1997; Assersohn et al. 2004). For many decades, 5-ﬂ  uorouracil 
(5-FU), oral ﬂ  uorpyrimidines combined with cisplatin have been the basis of most chemotherapy regimens 
for both cancer types (Waters et al. 1999; Schulze-Bergkamen et al. 2002; Vanhoefer et al. 2000). 556
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For pancreatic cancer, gemcitabine has also been 
established as a palliative standard treatment (Burris 
et al. 1997), with a median 12 month survival of 
18%. (Burris et al. 1997; Rothenberg et al. 1996). 
Despite many efforts to improve outcome by 
combinations of these or other cytotoxic substances, 
the results remain still disappointing with a 5 year 
survival rate less than 5% after diagnosis of 
unresectable/metastatic gastric or pancreatic cancer 
(Louvet et al. 2005; Colucci et al. 2002; Berlin et al. 
2002; Jemal et al. 2005; Moehler et al. 2003; 
Moehler et al. 2005; Wagner et al. 2007; Eickhoff 
et al. 2006).
Thus, approximately half of all patients facing 
failure of upfront ﬁ  rst line chemotherapy are still 
in good performance status are willing to and 
clearly require additional treatment options as 
second-line treatment protocols.
Herein, taxanes have shown to represent an 
alternative cytotoxic class with clear antiproliferative 
activities in gastric and bilio-pancreatic malignancies 
in vitro and in vivo (Hanauske et al. 1992; Tanaka 
et al. 1996). Both taxanes, docetaxel or paclitaxel 
promote microtubule stabilisation by increasing 
tubulin polymerisation, causing cell cycle arrest 
in the G2/M phase. After promosing phase II tri-
als have conﬁ  rmed the activity of docetaxel as 
single agent, treatment for gastric cancer achieved 
response rates between 16 and 24% (Bang et al. 
2002; Einzig et al. 1996; Mai et al. 1999; 
Mavroudis et al. 2000; Van Cutsem et al. 2008). 
Furthermore, the combination of docetaxel, cis-
platin and 5-FU has recently been approved as 
one new standard regimen in advanced gastric 
cancer (Van Cutsem et al. 2006; Park et al. 2006; 
Ajani et al. 2005).
To establish a possible salvage therapy in gastric 
and pancreatic cancer after failure of standard 
upfront therapies, we analysed the tolerability and 
clinical effects of a weekly docetaxel regimen in 
pretreated and chemo-resistant patients with gastric 
or pancreatic cancers.
Patients and Methods
Patients
After informed consent, patients were consecutively 
recruited into the monocentric study. Eligible 
patients had pretreated histological proven gastric 
or bilio-pancreatic adenocarcinomas. All patients 
had measurable lesions as deﬁ  ned by RECIST 
criteria or quantiﬁ  able non target lesions. Patients 
who had no previous chemotherapeutic treatment 
were excluded.
Administration of study drugs 
and dose adjustment
Assigned patients received docetaxel as weekly 
intravenous infusion over 60 minutes. After three 
subsequent weekly administrations docetaxel was 
omitted for one week. The mean docetaxel dose 
reached 38 mg/m² body surface. Antiemetic pre-
medication consisted of granisetron (1 mg) and 
dexamethasone (8 mg). If indicated, prophylactic 
anti-anaphylactic and anti-emetic treatment 
included dexamethason 8 mg throughout the ﬁ  rst 
two days after chemotherapy once daily. Dose 
adjustments of docetaxel were performed if side 
effects associated to chemotherapy were graded as 
severe or life threatening. Patients received the 
palliative treatment of docetaxel between July 2001 
and May 2006 (57 months). All side effects were 
deﬁ  ned following the National Cancer Institute 
common toxicity criteria (NCI-CTC), version 
2 (Moehler et al. 2005).
After ﬁ  rst occurrence of chemotherapy asso-
ciated side effects chemotherapy was stopped 
until associated toxicity disappeared. Recurrent 
side effects lead to 20% dose reductions of 
docetaxel for up to two times. Docetaxel was 
administered until disease progression or unac-
ceptable and persisting toxicity or withdrawal of 
consent.
Study evaluations
At baseline up to ﬁ  ve measurable lesions per organ 
and ten lesions in total were to be identiﬁ  ed as 
target lesions. These were measured using 
computed tomography (CT), and recorded 
according to the RECIST system (Response 
Evaluation Criteria In Solid Tumors) (Therasse 
et al. 2000). The sum of the longest diameters for 
all target lesions was used as a reference for 
determining objective tumor response. Quantiﬁ  able 
non target lesions were chosen alternatively to 
monitor treatment response if required. Tumor 
responses were evaluated after an average of 
11 weeks representing about three cycles of 
chemotherapy. Patients were followed for an 
average of 6.9 months (median 4.5 months). 
Complete response (CR) was defined as the 
disappearance of all target and non-target lesions 557
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with no new lesions. Partial remission (PR) was 
deﬁ  ned as a reduction of 30% or more in the sums 
of the longest diameters of all measurable lesions 
relative to baseline with no new lesions; Stable 
disease (SD) was deﬁ  ned as neither sufﬁ  cient 
shrinkage to qualify for PR nor sufﬁ  cient increase 
to qualify for progressive disease (PD) with no new 
lesions; PD was deﬁ  ned as 20% increase in the 
sum of the longest diameters or the occur-
rence of non-target lesions (e.g. pleural effusion 
or ascites). Safety and tolerability were assessed 
weekly by regular clinical examinations and 
assessments of adverse events during administra-
tion of chemotherapy. Monitored parameters of 
safety and tolerability referred to disease symptoms 
and haematological and biochemical parameters.
Results
Patient characteristics
Eighteen patients were evaluated in this study. The 
median age of all patients was 59.5 years. In 72% 
(13/18) of all patients the primary tumor site was 
gastric and in 28% (5/18) bilio-pancreatic, with 
only one patient with cholangiocarcinoma. All 
patients had metastatic disease and in 78% (14/18) 
two or more organs were involved (Table 1). 
One third showed ascites or radiological signs 
suspicious for peritoneal carcinomatosis.
Every patient with gastric cancer had received 
a 5-FU or capecitabine based regimen prior to 
docetaxel. These pretreatments were combined 
with cisplatin, irinotecan or etoposide, in 84% 
(11/13), 69% (9/13) or in 23% (3/13), respectively. 
Thus in the gastric cancer subgroup all patients had 
previously been treated with either cisplatin or 
irinotecan. Two patients additionally had 
radio-chemotherapy pretreatment. Also patients 
with bilio-pancreatic cancer were previously 
treated with gemcitabine based chemotherapy 
schedules, which was administered as ﬁ  rst line in 
80% (4/5). Patients with bilio-pancreatic carcinoma 
also had received 5-FU or oxaliplatin in 60% (3/5) 
each (Table 2).
Safety
A median number of nine chemotherapy cycles 
was administered during the observed study 
period. Dose administration delays became man-
datory in 61% (11/18) and the absolute number of 
treatment delays accounted for 16% of   all 
docetaxel infusions. Dose reductions were per-
formed in 17% (3/18) of all patients and were 
limited to only one dose reduction of  20%. The 
main reason for discontinuing study treatment was 
Table 1. Patient characteristics.
Primary tumor site
Gastric (n = 13) Bilio-pancreatic (n = 5)
Gender (male/female) 13/0 1/5
Age (median), years (range) 58 (47–69) 63 (56–68)
Metastatic sites
Hepatic 10 5
Pulmonal 4 0
Lymphatic/nodal 10 4
Skeletal 2 –
Peritoneal 1 –
other sites 3 –
No. of metastatic sites
0– –
13 1
24 4
3 60558
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Table 2. Pre-treatments of study population.
Primary tumor site
Gastric
(%)
Bilio-pancreatic
(%)
5-FU/Capecitabine 13 (100) 4 (80)
Cisplatin 11(85) –
Irinotecan 9 (69) –
Etoposid 3 (23) –
Interferon 1(7.7) –
Gemcitabine – 5 (100)
Oxaliplatin – 3 (60)
Table 3a. Haematological toxicities.
No. Patients (%)
NCI-CTC Grade 1 2 3 4 3–4 1–4
Leukopenia – 1 2 1 3 (16.5) 4 (22)
Neutropenia – 1 1 – 1(5.5) 2 (11)
Anemia 3 2 – – – 5 (28)
Table 3b. Non–haematological toxicities.
No. Patients (%)
NCI-CTC Grade 1 2 3 4 3–4 1–4
Nausea/vomiting 8 5 3 – 3 (16.5) 6 (33)
Polyneuropathy 2 1 3 – 3 (16.5) 6 (33)
Anorexia 4 4 2 – 2 (11.0) 10 (56)
Dyspnea 1 2 1 – 1 (5.5) 4 (22)
Edema 2 5 1 – 1 (5.5) 8 (44)
Fatigue 4 2 1 – 1 (5.5) 7 (39)
Mucositis 2 2 1 – 1 (5.5) 5 (28)
Alopecia 2 2 – – – 4 (22)
Diarrhoea 2 4 – – – 6 (33)
disease progression. The primary reason responsible 
for treatment adjustments (dose reduction and 
treatment delay), were leucopenia and infection. 
In contrast, the most common chemotherapy-
associated side effects were anorexia, edema, 
nausea/vomiting and toxic polyneuropathy. The 
incidence of haematological toxicities, grade 3 to 
4, with an overall rate of 22%, (4/18) was low 
compared to other docetaxel infusions (Van 
Cutsem et al. 2006) (Tables 3a/b). Fatal infectious 
complications (NCI-CTC, Grade 4) were observed 
in one case but could not be attributed directly to 
chemotherapy.
Response rates
The tumor control rate (CR + PR + SD) of all 
patients for the entire treatment period including 
all assessments prior to discontinuation was 
33% (6/18). The mainstay of patients showed 
stable disease whereas only one patient showed 
a partial response and no patient developed 
complete responses. Analysis of the patients 
suffering from gastric cancer revealed a tumor 
control rate of 38.5% (5/13). Bilio-pancreatic 
tumors showed a tumor control rate of only 20% 
(1/5) (Table 4).
Progression-free survival, treatment 
failure and overall survival
The median follow-up was 57 months at the last 
data cut-off. At this time, 15 of 18 patients had 
died. Disease progression was responsible for 
mortality in 87% of all cases during this study. One 
patient died from sepsis-related complications, 
which were not prompted by chemotherapy 
associated neutropenia. Median progression-free 
survival, median time to treatment failure and 
median overall survival are listed in Table 5.
Discussion
Although chemotherapy regimens for gastric 
cancer and bilio-pancreatic cancer offer improve-
ments in survival or quality of life, nearly all 
patients eventually progresses. The endpoints 
chosen in this clinical analysis was time till pro-
gression after initiation of docetaxel and overall 
survival after ﬁ  rst administration of docetaxel. 
In this analysis we observed an overall survival 
of 6.9 months (median 4.5 months) and a time 
till progression of  3.1 months (median 2.4 months) 
after initiation of docetaxel. As many patients 
have received multiple pre-treatments with 
standard chemotherapy protocols, response rates 
were predictably low. In this highly pretreated 
patient population overall response rates of 
33.3% (PR and SD) are still remarkable as cross 
resistance has been described for multiple malig-
nant entities.
When patient histories, disease status and other 
factors were examined for their effects on clinical 
outcome, those patients who were in better general 
health (good performance status, low tumor burden) 559
Docetaxel as salvage therapy in highly pretreated and drug resistant gasrointestinal carcinomas
Clinical Medicine: Oncology 2008:2
Table 4. Response.
Primary tumor site
Gastric (%) Bilio-pancreatic (%) Total (%)
Complete Response 0 (0) 0 (0) 0 (0)
Partial response 1 (7.7) 0 (0) 1 (5.5)
Stable disease 4 (30.8) 1 (20) 5 (27.7)
Tumor control rate 
(CR + PR + SD)
5 (38.5) 1 (20) 6 (33.3)
Progressive disease 8 (61.5) 4 (80) 12 (66.7)
Table 5.  Survival.
Primary tumor site
Gastric months 
(Median)
Bilio-pancreatic months 
(Median)
Total months 
(Median)
Progression free survival 2.9 (2.1) 3.5 (2.4) 3.1 (2.4)
Survival after docetaxel  6.5 (4.9) 9.5 (4.2) 6.9 (4.5)
Overall survival 25.9 (22.8) 22.1 (20.6) 24.3 (20.6)
were more likely to achieve a response and less 
likely to have a progression event or die, regardless 
of  the treatment chosen for palliative chemotherapy. 
Results from prospective clinical trials investigating 
the effects of peritoneal carcinomatosis ascites on 
patient survival predicted a mean survival for 
gastric cancer of 3.1 months. For pancreatic cancer, 
the results were even more fatal showing a mean 
survival of  2.1 months if peritoneal effusions have 
developed (Chu et al. 1989; Rau et al. 1996; 
Sadeghi et al. 2000). Thus, our limited response 
rates to docetaxel may be partially explained by 
the special characteristics of our study population, 
as our mostly highly pretreated patients developed 
extended tumor stages before salvage chemotherapy 
could be initiated and ascites and radiological 
indicators for peritoneal carcinomatosis were 
present in 33%, also in agreement to other trials 
(Sadeghi et al. 2000).
Despite fatal prognoses some individual patients 
showed an overall survival, which was longer than 
expected. This indicates that some malignancies 
with speciﬁ  c biological patterns might respond to 
salvage therapy. Whereas the median survival was 
limited, remarkably enough some patients survived 
more than 5 years, with the longest overall survival 
of 8.4 years for a patient suffering from metastatic 
gastric carcinoma. Another patient diagnosed with 
cholangiocarcinoma and an overall survival of 
more than two years indicating that some patients 
might benefit from salvage treatment. Taken 
together about 27% (5/18) of all individuals were 
able to experience an overall survival of more than 
2.5 years. After all, the primary tumor site had a 
substantial impact on prognosis. In this context it 
was observed that pancreatic neoplasm were 
associated with worse outcomes than gastric 
carcinoma.
Given that not all patients will beneﬁ  t from 
salvage treatment, safety of chemotherapy is an 
essential issue, which was addressed in this 
retrospective analysis. We conducted an analysis 
of all patient out-clinic visits and were able to 
extract all relevant side effects. Despite extended 
tumor disease only one patient experienced a life 
threatening complication, which was not conclusively 
attributed to docetaxel. Most signiﬁ  cant side effects 
(NCI-CTC, grade 3–4) were caused by haemato-
logical toxicity, affecting 22% of all patients. In 
this observation polyneuropathy and nausea, both 
in 16.5% of all patients, were other common 
toxicities (NCI-CTC, grade 3–4) of docetaxel. In 
contrast, clinical trials investigating single agent 
docetaxel as ﬁ  st-line treatment have shown a much 560
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higher leucopenia and/or neutropenia rates of 
80 to 90% (Bang et al. 2002; Einzig et al. 1996; 
Sulkes et al. 1994; Lorenzen, 2007; Van Cutsem 
et al. 2006). These results are also in agreement 
with trials investigating docetaxel as second-line 
chemotherapy, which report a similar haemato-
logical toxicity affecting 14% to 18% of all patients 
(Graziano et al. 2000; Giuliani et al. 2003). There-
fore docetaxel is a manageable salvage treatment 
option with potential beneﬁ  t for patients with 
refractory gastric and bilio-pancreatic carcinoma 
and further prospective trials are warranted to 
conﬁ  rm this retrospective analysis.
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